Unique ID issued by UMIN | UMIN000001510 |
---|---|
Receipt number | R000001814 |
Scientific Title | A phase II randomized trial in completely resected non-small cell lung cancer comparing paclitaxel / carboplatin with TS-1 |
Date of disclosure of the study information | 2008/11/18 |
Last modified on | 2012/11/18 23:01:21 |
A phase II randomized trial in completely resected non-small cell lung cancer comparing paclitaxel / carboplatin with TS-1
A phase II randomized trial in completely resected non-small cell lung cancer (PTX/CBDCA vs TS-1)
A phase II randomized trial in completely resected non-small cell lung cancer comparing paclitaxel / carboplatin with TS-1
A phase II randomized trial in completely resected non-small cell lung cancer (PTX/CBDCA vs TS-1)
Japan |
non-small cell lung cancer
Chest surgery |
Malignancy
NO
To compare the efficacy of adjuvant chemotherapy with PTX/CBDCA and TS-1 for completely resected non-small cell lung cancer in stage II and IIIA
Efficacy
2-year relapse free survival
Interventional
Parallel
Randomized
Open -no one is blinded
Uncontrolled
2
Treatment
Medicine |
A: paclitaxel 120mg/m2 + carboplatin AUC 3, day1 and day15, q4w, 4 course
B: TS-1 80mg/m2 oral, day1 to 14, q3w, 1 year
20 | years-old | <= |
76 | years-old | > |
Male and Female
1) pathologically proven non-small cell lung cancer
2) completely resected by lobectomy or pneumonectomy (+ other resection)
3) pathological stage II or IIIA (IASCL ver.7)
4) no prior chemotherapy or radiotherapy
5) PS 0 or 1
6) age 20-75
7) adequate organ function
.WBC>=3500/mm3<=12000/mm3
.neutrophil<=2000/mm3
.platelet<=100000/mm3
.AST,ALT within 2 times of upper limit
.total bilirubin within 2 times of upper limit
.SpO2>=95%
.creatinin within upper limit
.creatinin clearance>=60ml/min/body
8) possible to receive chemotherapy within 8 weeks after surgery
9) oral intake possible
10) written informed consent
1) apparent interstitial pneumonitis or pulmonary fibrosis
2) uncontroled pleural effusion or ascitis
3) multiple lung cancer
4) concomittant malignanct
5) past history of radiotherapy or chemotherapy
6) active infection or uncontroled complication
7) past history of severe allergic reaction
8) Pregnant or expecting woman
9) other conditions not suitable for this study
100
1st name | |
Middle name | |
Last name | Motoki Yano |
Nagoya City University Hospital
Department of thoracic Surgery
1 Kawasumi, Mizuho-cho, Mizuho-ku, Nagoya
1st name | |
Middle name | |
Last name | Motoki Yano |
Nagoya City University Graduate school of Medical Sciences
Department of Oncology, Immunology, and Surgery
Nagoya City University thoracic oncology study group
Nagoya City University Graduate school of Medical Sciences
Self funding
NO
2008 | Year | 11 | Month | 18 | Day |
Unpublished
2008 | Year | 11 | Month | 07 | Day |
2008 | Year | 11 | Month | 01 | Day |
2013 | Year | 10 | Month | 01 | Day |
2008 | Year | 11 | Month | 18 | Day |
2012 | Year | 11 | Month | 18 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000001814
Research Plan | |
---|---|
Registered date | File name |
Research case data specifications | |
---|---|
Registered date | File name |
Research case data | |
---|---|
Registered date | File name |